Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy;Alogena transplantacija matičnih ćelija u lečenju hronične granulocitne leukemije kao još uvek prihvatljiv pristup u eri nove ciljne terapije

Vojnosanitetski Pregled

Volumn 69, Issue 1, 2012, Pages 37-42

  Stamatović, Dragana ^a   Balint, Bela ^a   Tukić, Ljiljana ^a   Elez, Marija ^a   Tarabar, Olivera ^a   Todorović, Milena ^b   Todorić Živanović, Biljana ^a   Ostojić, Gordana ^a   Tatomirović, Željka ^a   Marjanović, Slobodan ^a   Malešević, Milomir ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Bcr abl positive; Chronic; Homologous; Leukemia; Myelogenous; Stem cells; Transplantation; Treatment outcome

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; IMATINIB; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; ENGRAFTMENT; FEMALE; HUMAN; LEUKEMIA RELAPSE; MALE; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; POLYMORPHONUCLEAR CELL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; THROMBOCYTE; TRANSPLANT RELATED MORTALITY SCORING SYSTEM;

ADOLESCENT; ADULT; CHILD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84855677061     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1201037S     Document Type: Article

References (35)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-501.
2. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977; 63(1): 125-30.
3. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61(7): 1441-6.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341(3): 164-72.
5. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10(5): 772-8.
6. Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H. et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irra diation and marrow transplantation from an identical twin. N Engl J Med 1979; 300(7): 333-7.
7. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998; 91(5): 1810-9.
8. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352(9134): 1087-92.
9. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91(4): 513-21.
10. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32(9): 897-901.
11. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101(2): 469-72.
12. Weisser M, Schleuning M, Ledderose G, Rolf B, Schnittger S, Schoch C, et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34(12): 1083-8.
13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5): 561-6.
14. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99(10): 3547-53.
15. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530-9.
16. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408-17.
17. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J. et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111(3): 1039-43.
18. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90(11): 850-8.
19. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314(12): 729-35.
20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15(6): 825-8.
21. Kantarjian HM, Giles FJ, O'Brien S, Giralt S, Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer 2000; 89(8): 1647-58.
22. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435(7046): 1267-70.
23. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125(5): 613-20.
24. Gallardo D, de la Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009; 94(9): 1282-8.
25. Balint B. Stem and progenitor cell harvesting, extracorporeal 'graft engineering' and clinical use: Initial expansion vs. current dilemmas. Clin Appl Immunol 2006; 5(1): 518-27.
26. Balint B, Ljubenov M, Stamatović D, Todorović M, Pavlović M, Ostojić G, et al. Stem cell harvesting protocol research in autologous transplantation setting: large volume vs. conventional cytapheresis. Vojnosanit Pregl 2008; 65(7): 545-51.
27. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106(9): 2969-76.
28. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408-17.
29. Gupta A, Prasad K. Hematological and molecular response evaluation of CML patients on imatinib. J Assoc Physicians India 2007; 55: 109-13.
30. Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008; 93(5): 770-4.
31. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111(4): 1834-9.
32. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109(10): 4143-50.
33. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108(6): 1809-20.
34. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91(4): 452-9.
35. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109(4): 1782-9.